Yosemite is a US based venture capital firm founded by Reed Jobs to back companies and researchers working to transform cancer from a deadly diagnosis into a manageable disease. The firm invests across oncology, gene therapy, AI driven drug discovery, and deep scientific innovation. Yosemite operates with a dual mandate of venture investing and scientific grant making, positioning itself as an early supporter of breakthroughs long before they are ready for commercial capital.
Yosemite has raised more than 200 million dollars toward its second fund, which targets 350 million dollars in total commitments. Fund II brings together a group of high powered LPs, including Amgen, Memorial Sloan Kettering, MIT, and venture capitalist John Doerr. Laurene Powell Jobs, through Emerson Collective, is also an investor, and Reed Jobs is personally committed as a general partner.
The fund will invest in about 25 companies across oncology and adjacent therapeutic areas. Yosemite’s hybrid grants plus venture model gives it early access to frontier scientific innovations and allows the firm to support researchers at the earliest and most fragile phase of discovery.
Fund II will invest in cancer vaccines, radiopharmaceuticals, gene therapy, and AI enabled drug development as well as technologies that make healthcare operationally more efficient. Yosemite now manages more than a billion dollars in assets across endowments, hospitals, and foundations.
Leadership
The firm is led by founder and managing director Reed Jobs, who previously built the oncology investment and philanthropy strategy at Emerson Collective. He works with a network of scientific advisers and institutional partners across biotech, cancer research, and academia.
Investment Strategy
Yosemite invests in fundamental scientific breakthroughs with the potential to redefine cancer care. The firm focuses on high risk, high impact innovation and bridges the gap between academic discovery and commercial readiness. Yosemite supports companies with both grants and equity capital to accelerate translational research, early clinical proof, and platform development. The strategy emphasizes disease biology, long term therapeutic potential, and catalytic effects on the wider cancer ecosystem.
Notable Investments
Portfolio companies include:
Yosemite has also supported dozens of researchers with grants that later led to venture backed company formation.
Notable Exits
Not publicly disclosed.
Other
Yosemite stands out for its integrated model combining scientific grants and venture investing, giving the firm early pipeline access and strong ties to leading research labs. The firm focuses on founders and scientists pushing the boundaries of oncology, with an emphasis on gene therapy, cancer vaccines, AI designed proteins, and next generation targeted therapies.
United States
